Edgewise Therapeutics, Inc. $EWTX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Edgewise by 104.8% in Q4 to 271,385 shares (about 0.26% of the company) valued at roughly $6.73 million.
• Analysts are broadly constructive with an average rating of "Moderate Buy" and a mean price target of $38.44; notable calls include JPMorgan raising its target to $45 (Overweight) and Raymond James at $46, while HC Wainwright has a Strong Buy.
• Shares trade near $30.64 (52‑week range $12.15–$35.00) following a quarterly EPS miss (‑$0.47 vs. ‑$0.43), and CMO Joanne M. Donovan recently sold 28,662 shares (~$926k); insiders own 23.2% of the company.

Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 104.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 271,385 shares of the company's stock after buying an additional 138,882 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.26% of Edgewise Therapeutics worth $6,734,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in EWTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Edgewise Therapeutics by 6.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,776 shares of the company's stock worth $963,000 after buying an additional 2,463 shares in the last quarter. Jones Financial Companies Lllp purchased a new position in Edgewise Therapeutics in the 1st quarter valued at about $47,000. Goldman Sachs Group Inc. lifted its holdings in Edgewise Therapeutics by 5.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 366,644 shares of the company's stock valued at $8,066,000 after purchasing an additional 19,753 shares in the last quarter. Strs Ohio purchased a new position in Edgewise Therapeutics in the 1st quarter valued at about $84,000. Finally, Creative Planning lifted its holdings in Edgewise Therapeutics by 29.4% in the 2nd quarter. Creative Planning now owns 16,910 shares of the company's stock valued at $222,000 after purchasing an additional 3,837 shares in the last quarter.

Analyst Ratings Changes

EWTX has been the topic of a number of recent research reports. Raymond James Financial set a $46.00 target price on shares of Edgewise Therapeutics in a report on Tuesday, March 10th. Wall Street Zen lowered shares of Edgewise Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, February 28th. Piper Sandler restated an "overweight" rating on shares of Edgewise Therapeutics in a report on Monday, February 9th. HC Wainwright upgraded shares of Edgewise Therapeutics to a "strong-buy" rating in a report on Thursday, February 26th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Edgewise Therapeutics from $34.00 to $45.00 and gave the stock an "overweight" rating in a report on Tuesday, March 17th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $38.44.

Edgewise Therapeutics Stock Down 3.0%

Shares of NASDAQ:EWTX opened at $30.64 on Tuesday. Edgewise Therapeutics, Inc. has a 52-week low of $12.15 and a 52-week high of $35.00. The company has a 50 day moving average of $31.06 and a two-hundred day moving average of $26.03. The company has a market capitalization of $3.29 billion, a price-to-earnings ratio of -18.80 and a beta of 0.24.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.04). On average, equities analysts anticipate that Edgewise Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Insider Activity at Edgewise Therapeutics

In other news, CMO Joanne M. Donovan sold 28,662 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $32.31, for a total transaction of $926,069.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 23.20% of the company's stock.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc NASDAQ: EWTX is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise's pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.

Want to see what other hedge funds are holding EWTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.